Related Experiment Video

Updated: Mar 25, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.3K

Metformin regulates oxLDL-facilitated endothelial dysfunction by modulation of SIRT1 through repressing

Ching-Hsia Hung1,2, Shih-Hung Chan3, Pei-Ming Chu4

  • 1Department of Physical Therapy, College of Medicine, National Cheng Kung University,Tainan, Taiwan.

Oncotarget
|February 18, 2016
PubMed

Insights

Metformin protects human endothelial cells from oxidative damage by increasing SIRT1 and AMPK expression. This action inhibits oxidized LDL (oxLDL) effects, revealing metformin's protective molecular mechanisms.

Area of Science:

  • Cardiovascular Biology
  • Endothelial Cell Function
  • Molecular Medicine

Background:

  • Oxidized low-density lipoprotein (oxLDL) is implicated in atherosclerosis development.
  • Oxidative stress and reactive oxygen species (ROS) modulate endothelial cell responses.
  • Understanding metformin's effects on endothelial cells is crucial for cardiovascular health.

Purpose of the Study:

  • To investigate the molecular mechanisms of metformin's protective effects in human umbilical vein endothelial cells (HUVECs).
  • To determine the role of SIRT1 and AMPK in mediating metformin's actions against oxLDL-induced injury.

Main Methods:

  • HUVECs were treated with oxLDL and metformin.
  • Expression levels of SIRT1, AMPK, LOX-1, AKT, and eNOS were analyzed.
  • SIRT1 and AMPK were silenced to assess their role in metformin's protective effects.

Main Results:

  • Metformin enhanced SIRT1 and AMPK expression in HUVECs.
  • Metformin inhibited oxLDL-induced LOX-1 expression.
  • Metformin prevented oxLDL-induced reduction in AKT/eNOS levels.
  • Silencing SIRT1 and AMPK abolished metformin's protective effects against oxidative injury.

Conclusions:

  • Metformin exerts protective effects on HUVECs against oxLDL-induced oxidative injury.
  • The protective mechanisms involve the upregulation of SIRT1 and AMPK.
  • These findings elucidate novel molecular pathways for metformin in cardiovascular disease prevention.
Keywords:
GerotargetSIRT1endothelial dysfunctionmetforminoxLDL

More Related Videos

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

1.2K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
919
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K
Regulation of Metabolism01:19

Regulation of Metabolism

Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
12.2K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
5.9K
Phase I Oxidative Reactions: Overview01:19

Phase I Oxidative Reactions: Overview

Phase I biotransformation, or functionalization, is a crucial chemical process that converts drugs and other xenobiotics into more water-soluble forms, facilitating expulsion from the body. It involves oxidative, reductive, and hydrolytic reactions that add or unveil polar functional groups on lipophilic substrates. Key players in phase I reactions are the mixed-function oxidases. Situated in liver cell microsomes, these enzymes predominantly carry out drug metabolism. They require molecular...
990
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
845